Table 3.
Overall seroprevalence of HEV 71 and/or CVA 16 antibody
| Year | No. of tested | No. (%) of positive | ||
|---|---|---|---|---|
| HEV 71 | CVA 16 | Co-infection | ||
| 2014 (before) | ||||
| Male | 171 | 80 (46.78) | 93 (54.39) | 58 (33.92) |
| Female | 129 | 71 (55.04) | 75 (58.14) | 54 (41.86) |
| Total | 300 | 151 (50.33) | 168 (56.00) | 112 (37.33) |
| 2014 (after) | ||||
| Male | 116 | 83 (71.55) | 71 (61.21) | 58 (50.00) |
| Female | 64 | 48 (75.00) | 40 (62.50) | 35 (51.56) |
| Total | 180 | 131 (72.78) | 111 (61.67) | 93 (50.56) |
| 2015 (before) | ||||
| Male | 106 | 46 (43.40) | 60 (56.60) | 35 (33.02) |
| Female | 94 | 41 (43.62) | 42 (44.68) | 27 (28.72) |
| Total | 200 | 87 (43.50) | 102 (51.00) | 62 (31.00) |
| 2015 (after) | ||||
| Male | 111 | 76 (68.47) | 87 (78.38) | 61 (54.95) |
| Female | 89 | 53 (59.55) | 63 (70.79) | 42 (47.19) |
| Total | 200 | 129 (64.50) | 150 (75.00) | 103 (51.50) |
| 2016 (before) | ||||
| Male | 118 | 41 (34.75) | 29 (24.58) | 9 (7.63) |
| Female | 82 | 23 (28.05) | 21 (25.61) | 11 (13.41) |
| Total | 200 | 64 (32.00) | 50 (25.00) | 20 (10.00) |
| 2016 (after) | ||||
| Male | 76 | 27 (35.53) | 46 (60.53) | 21 (27.63) |
| Female | 74 | 32 (43.24) | 40 (54.05) | 27 (36.49) |
| Total | 150 | 59 (39.33) | 86 (57.33) | 48 (32.00) |
| Overall | ||||
| Male | 698 | 353 (50.57) | 386 (55.30) | 242 (34.67) |
| Female | 532 | 268 (50.38) | 281 (52.82) | 196 (36.84) |
| Total | 1230 | 621 (50.49) | 667 (54.23) | 438 (35.61) |